[go: up one dir, main page]

MX2016015464A - Composicion farmaceutica oral de isotretinoina. - Google Patents

Composicion farmaceutica oral de isotretinoina.

Info

Publication number
MX2016015464A
MX2016015464A MX2016015464A MX2016015464A MX2016015464A MX 2016015464 A MX2016015464 A MX 2016015464A MX 2016015464 A MX2016015464 A MX 2016015464A MX 2016015464 A MX2016015464 A MX 2016015464A MX 2016015464 A MX2016015464 A MX 2016015464A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral pharmaceutical
isotretinoin
present
preparing
Prior art date
Application number
MX2016015464A
Other languages
English (en)
Inventor
Kumar Madan Harish
Madan Sumit
Rao Rajesh
Barat Singh Romi
Venkateshwaran Rathinasabapathy
Kochhar Ravi
Santosh Jena Simon
Kumar Fanda Anuj
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2016015464A publication Critical patent/MX2016015464A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica oral de isotretinoína con una dosis reducida. La presente invención además se relaciona a un proceso para preparar la composición farmacéutica oral de la presente invención.
MX2016015464A 2014-06-02 2015-05-29 Composicion farmaceutica oral de isotretinoina. MX2016015464A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1456DE2014 2014-06-02
IN1737DE2014 2014-06-30
IN4002DE2014 2014-12-30
PCT/IB2015/054088 WO2015186039A1 (en) 2014-06-02 2015-05-29 Oral pharmaceutical composition of isotretinoin

Publications (1)

Publication Number Publication Date
MX2016015464A true MX2016015464A (es) 2017-03-27

Family

ID=54766227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015464A MX2016015464A (es) 2014-06-02 2015-05-29 Composicion farmaceutica oral de isotretinoina.

Country Status (10)

Country Link
US (2) US20160081965A1 (es)
EP (1) EP3148645A4 (es)
JP (1) JP2017516794A (es)
AU (1) AU2015270187A1 (es)
BR (1) BR112016028316A2 (es)
CA (1) CA2950533A1 (es)
MA (1) MA40313A (es)
MX (1) MX2016015464A (es)
RU (1) RU2016150868A (es)
WO (1) WO2015186039A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008556A2 (pt) 2015-10-30 2018-10-23 Patagonia Pharmaceuticals Llc ?composições farmacêuticas e métodos para tratar ictiose congênita?
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
CN109100454B (zh) * 2018-10-24 2021-08-06 中国日用化学研究院有限公司 一种同时测定表面活性剂产品中亚硫酸盐和硫酸盐含量的方法
WO2022091140A1 (en) * 2020-11-01 2022-05-05 Idrs Labs Pvt Ltd Oral liquid pharmaceutical compositions of isotretinoin
US20230270714A1 (en) * 2021-12-08 2023-08-31 ATAI Life Sciences AG Salvinorin compositions
IL318115A (en) 2022-07-01 2025-02-01 Acrotech Biopharma Inc Pharmaceutical preparations containing isotretinoin and processes for their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
CA2423170A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
MXPA04005497A (es) * 2001-12-06 2004-10-11 Ranbaxy Lab Ltd Composiciones nanoparticuladas de isotretinoin.
JP2010510988A (ja) * 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
AU2009334292A1 (en) * 2008-12-31 2010-07-08 Sunev Pharma Solution Limited Topical herbal formulation for treatment of acne and skin disorders
BRPI1010970A2 (pt) * 2009-05-20 2019-04-09 Ranbaxy Laboratories Limited solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento
CA2836228A1 (en) * 2012-12-13 2014-03-06 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin

Also Published As

Publication number Publication date
WO2015186039A1 (en) 2015-12-10
RU2016150868A3 (es) 2019-01-15
EP3148645A4 (en) 2017-11-15
MA40313A (fr) 2017-04-05
RU2016150868A (ru) 2018-07-17
BR112016028316A2 (pt) 2017-08-22
EP3148645A1 (en) 2017-04-05
US20160081965A1 (en) 2016-03-24
JP2017516794A (ja) 2017-06-22
AU2015270187A1 (en) 2016-12-15
CA2950533A1 (en) 2015-12-10
US20170326092A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
GEP20207074B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
IN2014CH00247A (es)
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20207076B (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20217239B (en) Pharmaceutical composition
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
MX370649B (es) Proceso para la preparacion de teneligliptina.
IN2013MU00646A (es)
MX2017002214A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
GEP20217240B (en) Pharmaceutical composition
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
IN2014MU00455A (es)
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
TW201613871A (en) Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene
HUE058627T2 (hu) Új eljárás nagy tisztaságú prosztaglandinok elõállítására
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
IN2014CH00840A (es)
EP3182981A4 (en) Process for the production of isomaltooligosaccharides
IN2013MU01113A (es)
IN2014CH00304A (es)
PL3223799T3 (pl) Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer
HUP1400025A1 (en) New dhydro-oxazinobenzodiazepine compounds a process for their preparation and pharmaceutical compositions containing them
IN2014CH01391A (es)